STOCK TITAN

[6-K] BRIGHT MINDS BIOSCIENCES INC. Current Report (Foreign Issuer)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File No. 001-40997

BRIGHT MINDS BIOSCIENCES INC.
(Translation of registrant's name into English)

 

400 N Aberdeen St Suite 900
Chicago, IL 60642
(U.S. Corporate headquarters)

1122 Mainland St #228
Vancouver, BC V6B 5L1
(Canadian Corporate headquarters)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  [ ]  Form 40-F  [ X ]


 

 

SUBMITTED HEREWITH

 

 

Exhibits

 

99.1

News Release dated January 6, 2026



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BRIGHT MINDS BIOSCIENCES INC.

 

/s/ Ryan Cheung  

Ryan Cheung
Chief Financial Officer

Date: January 6, 2026


Bright Minds Biosciences Inc

NASDAQ:DRUG

DRUG Rankings

DRUG Latest News

DRUG Latest SEC Filings

DRUG Stock Data

870.15M
6.21M
22.42%
73.98%
2.79%
Biotechnology
Healthcare
Link
United States
New York